Money
Filter News
Found 84,847 articles
-
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
4/17/2024
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the year ended December 31, 2023.
-
Awakn Life Sciences Announces Closing of Tranche of Private Placement
4/17/2024
Toronto, Ontario--(Newsfile Corp. - April 17, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with...
-
Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth
4/17/2024
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that...
-
Despite the strong performance of its cancer portfolio, Johnson & Johnson on Tuesday reported Stelara sales of $2.45 billion in the first quarter of 2024, falling short of Wall Street expectations of $2.6 billion.
-
The German biopharma company on Tuesday announced ambitious pipeline plans that include starting 10 new Phase II and III trials over the next 12 to 18 months.
-
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
4/16/2024
Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million.
-
Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Services
4/16/2024
Evergreen Theragnostics, Inc. today announced the successful completion of a $26M capital raise supported both by existing shareholders and new institutional investors, Petrichor and LIFTT.
-
Chimeron Bio receives NIH (NCI) Innovative Concept Award for mRNA cancer vaccine development
4/16/2024
Chimeron Bio, a Philadelphia -headquartered biotech company, has received a 2024 National Institutes of Health's Small Business Innovation Research Innovative Concept Award through the National Cancer Institute.
-
Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%
4/16/2024
Johnson & Johnson announced that its Board of Directors has declared a 4.2% increase in the quarterly dividend, from $1.19 per share to $1.24 per share, marking the 62nd year of consecutive increases.
-
Panbela Announces Transfer to OTCQB Market
4/16/2024
Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that its common stock has been approved for quotation on the OTCQB market.
-
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - April 16, 2024
4/16/2024
Annexon, Inc. announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.
-
Antibe Announces TSX Delisting Review
4/16/2024
Antibe Therapeutics Inc. announced that the Toronto Stock Exchange is reviewing the eligibility for continued listing on the TSX of the securities of the Company.
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - April 16, 2024
4/16/2024
Rhythm Pharmaceuticals, Inc. announced that on April 11, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 31,220 shares of its common stock to eight new employees, consisting of inducement stock options to purchase an aggregate of 16,480 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 14,740 shares of its common stock.
-
QSAM Announces Reverse Stock Split Ratio Ahead of Merger
4/16/2024
QSAM Biosciences, Inc. previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share, at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the Company and Telix Pharmaceuticals Limited pursuant to which Telix will acquire QSAM.
-
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
4/16/2024
TScan Therapeutics, Inc. announced that it has commenced an underwritten public offering of $125 million of shares of its voting common stock and, in lieu of voting common stock, to certain investors that so choose, pre-funded warrants to purchase shares of voting common stock.
-
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 16, 2024
4/16/2024
Chimerix announced that on April 10, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to four new employees of non-statutory stock options to purchase up to a total of 223,000 shares of Chimerix’s common stock.
-
Annoviant™ Awarded $2.99 Million NIH Grant to Advance TxGuard™ Pulmonary-Valved Conduit for Pediatric Heart Disease
4/16/2024
Annoviant™, Inc. proudly announces receipt of a $2.99 million grant from the National Institutes of Health.
-
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
4/16/2024
Cullinan Therapeutics, Inc. announced that it has entered into a stock purchase agreement with certain institutional and accredited investors for a private placement of approximately $274.0 million of shares of its common stock at a price of $19.00 per share and, in lieu of common stock to certain investors, $6.0 million of pre-funded warrants to purchase shares of its common stock at a price of $18.999 per pre-funded warrant.
-
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - April 16, 2024
4/16/2024
HOOKIPA Pharma Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-statutory options to Mark Winderlich, who was appointed Chief Development Officer of the Company effective April 1, 2024, to purchase an aggregate of 250,000 shares of the Company’s Common Stock under HOOKIPA’s 2023 Inducement Plan.
-
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
4/16/2024
Boehringer Ingelheim announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.